Dr. Novack’s presentations in 2014 include: FDA requirements for new drugs at Glaucoma 360 (Glaucoma Research Foundation), “Better Therapeutics in Glaucoma Through Drug Delivery” in the Innovator’s symposium at the American Society for Cataract & Refractive Surgery, and a Phase 2b study of AR-13324 in glaucoma and ocular hypertension at ARVO.

Dr. Novack continues to advise numerous companies on FDA interactions, including critical End of Phase 2 meetings, with frequent meetings with the FDA. Numerous investment firms have asked Dr. Novack’s advise on investments in innovative ophthalmic firms.